These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 35118917)

  • 1. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
    Jiang J; Li Y; Jiang Q; Jiang Y; Qin H; Li Y
    J Infect; 2024 Aug; 89(2):106190. PubMed ID: 38834107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis.
    Zheng Z; Zhou J; Song Y
    Iran J Med Sci; 2024 May; 49(5):275-285. PubMed ID: 38751873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
    Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
    Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Zur M; Peselev T; Yanko S; Rotshild V; Matok I
    Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proof-of-concept studies with a computationally designed M
    Papini C; Ullah I; Ranjan AP; Zhang S; Wu Q; Spasov KA; Zhang C; Mothes W; Crawford JM; Lindenbach BD; Uchil PD; Kumar P; Jorgensen WL; Anderson KS
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2320713121. PubMed ID: 38621119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    Tian F; Chen Z; Feng Q
    J Med Virol; 2023 Apr; 95(4):e28732. PubMed ID: 37183808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
    Jang YR; Oh Y; Kim JY
    J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
    J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation.
    Kwok WC; Tam TCC; Ho JCM; Lam DCL; Ip MS; Ho PL
    Int J Chron Obstruct Pulmon Dis; 2024; 19():77-86. PubMed ID: 38222320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.